Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019

Autor: Michael Smerina, Pramod Guru, Joshua Propst, Julio C. Mendez, Megan Melody, Jared Nelson, Jacquelyn Hastings
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
Case Report
Gastroenterology
Hypoxemia
chemistry.chemical_compound
0302 clinical medicine
Immunology and Allergy
Respiratory system
biology
inflammatory markers
lenzilumab
Combined Modality Therapy
Cytokine release syndrome
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
cytokine-release syndrome
medicine.symptom
Coronavirus Infections
Cytokine Release Syndrome
Respiratory Insufficiency
medicine.drug
medicine.medical_specialty
Immunology
Pneumonia
Viral
severe acute respiratory distress syndrome
Antibodies
Monoclonal
Humanized
03 medical and health sciences
Betacoronavirus
tocilizumab
Tocilizumab
Internal medicine
medicine
Humans
pneumonia
Interleukin 6
Pandemics
Aged
IL-6
business.industry
SARS-CoV-2
COVID-19
Granulocyte-Macrophage Colony-Stimulating Factor
Hydroxychloroquine
GM-CSF
medicine.disease
Receptors
Interleukin-6
COVID-19 Drug Treatment
Pneumonia
030104 developmental biology
Respiratory failure
chemistry
monoclonal antibody
biology.protein
business
Zdroj: Immunotherapy
ISSN: 1750-7448
Popis: Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19. Results & methodology: We present the case of a 68-year-old man with COVID-19 who was initially treated with hydroxychloroquine and lenzilumab, but continued to develop hypoxemia, requiring an increase in respiratory support with an associated rise in serum inflammatory markers. He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion & conclusion: This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome.
Databáze: OpenAIRE
Externí odkaz: